Aqua Bio Technology ASA: Primary insider notifications
Aqua Bio Technology ASA (ABTEC) · publisert 13. februar 2026 kl. 07:30 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Roger Sedal via Norlane AS | Styreleder | Tegning Emisjon/tegning | 99 720 | 5 NOK | 12. februar 2026 | – | Outside of trading venue |
| Terje Blytt via Terabyte Holding AS | director | Tegning Emisjon/tegning | 138 660 | 5 NOK | 12. februar 2026 | – | Outside of trading venue |
| Kristian Flaten via Caprock AS | CEO and CFO | Tegning Emisjon/tegning | 60 000 | 5 NOK | 12. februar 2026 | – | Outside of trading venue |
Vedlegg
- 260212 Notification Form NORLANE AS.pdf (application/pdf, originaldokument)
- Aqua Bio Technology ASA- Primary insider notifications.pdf (application/pdf, originaldokument)
- 260212 Notification Form TERABYTE HOLDING AS.pdf (application/pdf, originaldokument)
- 260212 Notification Form CAPROCK AS.pdf (application/pdf, originaldokument)
Meldingstekst
Reference is made to the stock exchange notices from Aqua Bio Technology ASA
("ABT" or the "Company") published on 12 February 2026 regarding the
successful placement of a private placement of 2,000,000 new shares (the "New
Shares") in the Company, at a subscription price of NOK 5.00 per New Share
(the "Private Placement"), corresponding to the par value of the shares of the
Company following a reverse share split to be implemented prior to formal
completion of the Private Placement.
The following primary insiders or close associates of primary insiders have
been allocated New Shares:
· Norlane AS, a company closely associated with Chairman Roger Sedal, was
allocated 99,720 New Shares, for a total subscription amount of NOK 498,600 to
be settled through conversion of debt.
· Terabyte Holding AS, a company closely associated with Board member Terje
Blytt, was allocated 138,660 New Shares, for a total subscription amount of
NOK 693,300 to be settled through conversion of debt.
· Caprock AS, a company closely associated with CEO and CFO Kristian Flaten,
was allocated 60,000 New Shares, for a total subscription amount of NOK
300,000 to be settled in cash.
Please see the attached notification forms for further information.
The issuance of the New Shares will be discussed in an extraordinary general
meeting to be held on 16 February 2026. The Company has secured sufficient
voting undertakings in order for the share capital increase in connection with
the Private Placement to be approved at the extraordinary general meeting.
This information is subject to the disclosure requirements pursuant to MAR
article 19.
Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA
Phone: +47 9509 2322
Email: kf@aquabiotech.no
About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.
This notice is published by Kristian Flaten on the listed date and time.
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-02-13 07:30
CET.